PMID- 19833178
OWN - NLM
STAT- MEDLINE
DCOM- 20100927
LR  - 20220409
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 390
IP  - 1
DP  - 2010 May 5
TI  - The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol.
PG  - 61-9
LID - 10.1016/j.ijpharm.2009.10.011 [doi]
AB  - The potential for colloidal carriers to increase drug bioavailability has spurred 
      a renewed interest in their uptake mechanisms and movement within cells. Solid 
      lipid nanoparticles (SLN) were used as a carrier for a promising chemopreventive 
      drug, resveratrol (RSV). The effects of SLN, empty or loaded with RSV (SLN-RSV), 
      on the internalization, growth, morphology, metabolic activity and genetic 
      material of keratinocytes were compared to those of RSV in solution. Fluorescence 
      images clearly showed that SLN with a size below 180 nm move promptly through the 
      cell membrane, distribute throughout the cytosol, move successively among 
      different cellular levels and localize in the perinuclear region without inducing 
      cytotoxicity. RSV solubility, stability and intracellular delivery were all 
      increased by loading into SLN. The release profile of RSV showed a biphasic 
      pattern, reflecting its distribution in SLN. RSV in solution was slightly 
      cytotoxic. That was prevented by loading it into solid lipid nanoparticles, which 
      preserved cell morphology. The cytostatic effect of SLN-RSV was much more 
      expressed than that of RSV in solution. Delivery of RSV by SLN contributes to 
      effectiveness of RSV on decreasing cell proliferation, with potential benefits 
      for prevention of skin cancer.
CI  - Copyright 2009 Elsevier B.V. All rights reserved.
FAU - Teskac, K
AU  - Teskac K
AD  - University of Ljubljana, Faculty of Pharmacy, Askerceva 7, Ljubljana, Slovenia.
FAU - Kristl, J
AU  - Kristl J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091013
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Carriers)
RN  - 0 (Lecithins)
RN  - 0 (Lipids)
RN  - 0 (Stilbenes)
RN  - 106392-12-5 (Poloxamer)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Anticarcinogenic Agents/administration & 
      dosage/metabolism/pharmacokinetics/pharmacology
MH  - Biological Availability
MH  - Cell Cycle/drug effects
MH  - Cell Line, Transformed
MH  - Cell Nucleus/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cell Shape/drug effects
MH  - Cell Size/drug effects
MH  - Delayed-Action Preparations/chemistry/metabolism/pharmacology
MH  - Drug Carriers/chemistry/*metabolism/pharmacology
MH  - Humans
MH  - Hydrophobic and Hydrophilic Interactions
MH  - Intracellular Space/metabolism
MH  - Keratinocytes/cytology/drug effects/*metabolism
MH  - Lecithins/chemistry
MH  - Lipids/*chemistry
MH  - Metabolism/drug effects
MH  - Microscopy, Fluorescence
MH  - Nanoparticles/*chemistry
MH  - Necrosis/chemically induced
MH  - Particle Size
MH  - Poloxamer/chemistry
MH  - Resveratrol
MH  - Static Electricity
MH  - Stilbenes/*administration & dosage/*metabolism/pharmacokinetics/pharmacology
EDAT- 2009/10/17 06:00
MHDA- 2010/09/29 06:00
CRDT- 2009/10/17 06:00
PHST- 2009/02/18 00:00 [received]
PHST- 2009/09/18 00:00 [revised]
PHST- 2009/10/03 00:00 [accepted]
PHST- 2009/10/17 06:00 [entrez]
PHST- 2009/10/17 06:00 [pubmed]
PHST- 2010/09/29 06:00 [medline]
AID - S0378-5173(09)00720-0 [pii]
AID - 10.1016/j.ijpharm.2009.10.011 [doi]
PST - ppublish
SO  - Int J Pharm. 2010 May 5;390(1):61-9. doi: 10.1016/j.ijpharm.2009.10.011. Epub 
      2009 Oct 13.